Andreas Viardot

12.2k citations

131 papers · 4.6k indexed · 3 hit papers · h-index 28

Impact in

Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment
Oncology top 0.5%
- CAR-T cell therapy research
- Viral-associated cancers and disorders

Papers in

Pathology and Forensic Medicine 92
- Lymphoma Diagnosis and Treatment 92
Genetics 52
- Chronic Lymphocytic Leukemia Research 52

Co-authors: Ralf C. Bargou Gerhard Zugmaier Matthias Stelljes Hermann Einsele Svenja Neumann Nicola Gökbuget Dieter Hoelzer Georg Heß
Journals: Blood (50 papers)Journal of Clinical Oncology (22 papers)British Journal of Haematology (5 papers)Annals of Hematology (5 papers)HemaSphere (4 papers)
Partner nations: Germany United States France

In The Last Decade

Andreas Viardot

124 papers receiving 4.5k citations

Hit Papers

align trajectories log scale

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma 2016 · 280 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2016 Blood
2014 Journal of Clinical Oncology
2008 Science

Peers

Countries citing papers authored by Andreas Viardot

Since Specialization

Citations

This map shows the geographic impact of Andreas Viardot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andreas Viardot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andreas Viardot more than expected).

Fields of papers citing papers by Andreas Viardot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andreas Viardot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andreas Viardot. The network helps show where Andreas Viardot may publish in the future.

Co-authors

The 25 scholars most cited alongside Andreas Viardot, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Andreas Viardot Line = papers co-authored together Andreas Viardot links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia Leukemia & lymphoma ·Fabian Lang, Andreas Voß, Guido Kobbe, Christian Junghanß, Joachim Beck, Andreas Viardot, Knut Wendelin, Jens Panse, عامر عجلان, Vladan Vučinić, Boris Böll, Max S. Topp, A. S. Andreeva, Hubert Serve, Nicola Goekbuget, Oliver G. Ottmann, Roman Pfeifer	2025	0
2	Update on GMALL Trial 08/2013 Shows Durable Favorable Outcome of Newly Diagnosed Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) with Imatinib, Dose-Reduced Induction Followed By Stem Cell Transplantation Blood ·Roman Pfeifer, Fabian Lang, Walter Fiedler, Matthias Stelljes, Folker Schneller, Björn Steffen, Boris Böll, Andreas Viardot, Christoph Faul, Lino L. Teichmann, Hendrik Poeck, Joerg Westermann, Kerstin Schäfer‐Eckart, Thomas Heinicke, Thomas Burmeister, Stefan Schwartz, Monika Brüggemann, Hubert Serve, Nicola Goekbuget	2024	2
3	Safety of AFM11 in the treatment of patients with B-cell malignancies: findings from two phase 1 studies Trials ·Max S. Topp, Monika Długosz‐Danecka, Aleksander B. Skotnicki, Yoko Toba-Ichihashi, Andreas Viardot, Andreas K. Klein, Georg Heß, Christian Michel, Sebastian Grosicki, Mothanna Alquraishi, Sylvia E. Schwarz, Vasyl Kashchyshyn, Mehmet Yüksel, Muḥammad al-H̱aḍir al-Ǧakanī (18..?-1935). Auteur du texte Šinqīṭī, Leila Alland, Jiřı́ Mayer	2023	9
4	Targeting CD19 in diffuse large B‐cell lymphoma: An expert opinion paper Hematological Oncology ·Sarah Bailly, Guillaume Cartron, Sridhar Chaganti, Raúl Córdoba, Paolo Corradini, 황종락, Isacco Ferrarini, Wendy Osborne, Andreas Rosenwald, Juan‐Manuel Sancho, Hervé Tilly, Eric Van Den Neste, Andreas Viardot, Carlo Visco	2022	10
5	Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial Leukemia & lymphoma ·Dominic Kaddu‐Mulindwa, Maggie Galliers, Christian Berdel, Stephan Stilgenbauer, Moritz Bewarder, Lorenz Thurner, Mathias Witzens‐Harig, Andreas Viardot, Martin Soekler, Ulrich Keller, Lorenz Truemper, Konstantinos Christofyllakis, Nerilda García-Alarcón, Joerg Thomas Bittenbring, Viola Poeschel, Gerhard Held, 秀秋百瀬	2021	2
6	A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial BMC Cancer ·D. Cionfrini, Lisa Kaiser, Jean-Christophe Boccon-Gibod, 杣彦立山, Andreas Viardot, Peter Mӧller, Thomas F.E. Barth, Rainer Muche, Jens Dreyhaupt, Markus Raderer, Barbara Kiesewetter, Christian Buske	2021	5
7	Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with B-Precursor Adult Lymphoblastic Leukemia (ALL): Results of the Ongoing GMALL Bold Trial Blood ·Nicola Goekbuget, Concepción Muñoz Tinoco, Max S. Topp, Stefan Schwartz, Mirna Awalianti, Christoph Faul, Bernd Hertenstein, Vladan Vučinić, Гульнара Флюновна Мусина, Anne C. Wilke, J. Chen, Diana Tichy, Monika Brüggemann, Andreas Viardot	2021	11
8	Perspektiven der CAR-T-Zell-Therapie Der Pathologe ·Andreas Viardot	2020	2
9	Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma Strahlentherapie und Onkologie ·Laila König, Klaus Herfarth, Juliane Hörner‐Rieber, Sascha Dietrich, Thomas Wiegel, Jürgen Debus, Andreas Viardot	2020	6
10	CD20 Expression and Response to Rituximab Treatment in B-Cell Precursor Lymphoblastic Leukemia - Results of the GMALL 08/2013 Trial Blood ·Monika Szczepanowski, Johanna Richter, La Asociación Nacional de Productores de Leche en Colombia, Matthias Ritgen, Heiko Trautmann, Henrik Knecht, Mustafa Kondakci, Christoph Faul, Björn Steffen, Andreas Viardot, Michael Kneba, Dieter Hoelzer, Nicola Goekbuget, Monika Brüggemann	2018	3
11	Primary Extranodal Diffuse Large B-Cell Lymphomas Are Enriched for Mutations in MYD88 and CD79B. Blood ·Stephanie E. Weissinger, Peter Möeller, Ralf Marienfeld, Johannes Bloehdorn, Andreas Viardot	2018	5
12	Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL -negative acute lymphoblastic leukemia Haematologica ·S Tedjini, Nicola Gökbuget, Stefan Schwartz, Richard Reinhardt, Monika Brüggemann, Andreas Viardot, Ralph Wäsch, Michael Starck, Eckhard Thiel, Dieter Hoelzer, Thomas Burmeister	2017	20
13	Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group Journal of Clinical Oncology ·Michael Pfreundschuh, Viola Poeschel, Samira Zeynalova, Mathias Hänel, Gerhard Held, Norbert Schmitz, Andreas Viardot, Martin Dreyling, Michael Hallek, A.N. Budzhelida, Martin H. J. Wiesen, Mathias Witzens‐Harig, Lorenz Truemper, Ulrich Keller, Tanja Rixecker, Carsten Zwick, Niels Murawski	2014	59
14	Optimization of rituximab for the treatment of DLBCL (I): dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL Annals of Oncology ·Niels Murawski, Michael Pfreundschuh, Samira Zeynalova, Viola Poeschel, Mathias Hänel, Gerhard Held, Norbert Schmitz, Andreas Viardot, Christian Schmidt, Michael Hallek, Mathias Witzens‐Harig, Lorenz Trümper, Léa Dias Rodrigues, C. Zwick	2014	48
15	Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1) The Lancet Oncology ·Norbert Schmitz, Maike Nickelsen, Marita Ziepert, Mathias Haenel, Peter Borchmann, Christian Schmidt, Andreas Viardot, Martin Bentz, Norma Peter, Gerhard Ehninger, Gottfried Doelken, Christian Ruebe, Lorenz Truemper, Andreas Rosenwald, Michael Pfreundschuh, Markus Loeffler, Bertram Glaß	2012	152
16	Micronuclei in peripheral blood from patients after cytostatic therapy mainly arise ex vivo from persistent damage Mutagenesis ·Sylvain Connac, (unknown), Swen Weßendorf, Martin Bommer, Andreas Viardot, Petra Schütz, G. Speit	2009	10
17	Cutaneous leukaemic infiltrations in a patient with previously undiagnosed myelodysplastic syndrome Clinical and Experimental Dermatology ·景一古川, Lutz Weber, Andreas Viardot, Mantaka Taimullah, R. Hinrichs, Karin Scharffetter‐Kochanek	2004	2
18	Cytogenetic evolution of follicular lymphoma Seminars in Cancer Biology ·Andreas Viardot, Thomas F.E. Barth, Peter Mӧller, Hartmut Döhner, Martin Bentz	2003	26
19	Detection of secondary genetic aberrations in follicle center cell derived lymphomas: assessment of the reliability of comparative genomic hybridization and standard chromosome analysis Leukemia ·Andreas Viardot, José I. Martı́n-Subero, Reiner Siebert, Svetlana Harder, Stefan Gesk, Martin Bentz, Brigitte Schlegelberger	2001	14
20	Gain of chromosome arm 9p is characteristic of primary mediastinal b-cell lymphoma (MBL): Comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line Genes Chromosomes and Cancer ·Martin Bentz, Thomas F.E. Barth, George Henry Cook, Bonny Lynn Dodson, Michael J. Schwerer, Michael Baudis, Stefan Joos, Andreas Viardot, Alfred C. Feller, Silvane Maria Fonseca Murta, Peter Lichter, W Fleischer, Cristiane dosSantos	2001	105

About Andreas Viardot

Andreas Viardot is a scholar working on Pathology and Forensic Medicine, Genetics, Oncology, Hematology and Public Health, Environmental and Occupational Health, having authored 131 papers that have together received 4.6k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (92 papers), CAR-T cell therapy research (54 papers), Chronic Lymphocytic Leukemia Research (52 papers), Acute Lymphoblastic Leukemia research (27 papers), Viral-associated cancers and disorders (17 papers), Monoclonal and Polyclonal Antibodies Research (15 papers), Chronic Myeloid Leukemia Treatments (13 papers) and CNS Lymphoma Diagnosis and Treatment (12 papers). The work is most often cited by research in Pathology and Forensic Medicine (2.0k citations), Oncology (3.0k citations), Genetics (806 citations), Hematology (842 citations) and Immunology (1.1k citations). Andreas Viardot has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Ralf C. Bargou, Gerhard Zugmaier, Matthias Stelljes, Hermann Einsele, Svenja Neumann, Nicola Gökbuget, Dieter Hoelzer, Georg Heß, Petra Klappers and Matthias Klinger. Their work appears in journals such as Blood, Journal of Clinical Oncology, British Journal of Haematology, Annals of Hematology and HemaSphere.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact